36 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22620 | any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Boehringer Ingelheim | 1367.1 | Trial closed | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 29694 | Francesco Sclafani | Multiple | Janssen | 61186372GIC2002 ORIGAMI-1 | Trial open for recruitment | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | francesco.sclafani@hubruxelles.be | 1/2 | 1 | ||
| 22698 | Unresacable metastasis. RECIST v1.1. Can receive FOLFOX | Alain Hendlisz | Colon | Celyad | Allo-Shrink | Trial closed | An open-label, Phase I study to assess the safety of multiple doses of CYAD-101, administered after standard FOLFOX chemotherapy in patients with unresectable metastatic colorectal cancer | alain.hendlisz@hubruxelles.be | 1 | 1 | |
| 22632 | any line, RECIST 1.1 | Philippe Aftimos | Multiple | Amcure GmbH | AMC303-01 | Trial closed | A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 29772 | Francesco Sclafani | Multiple | GSK | AZUR-2 219606 | Trial open for recruitment | A Phase 3, Double-Arm, Open-Label Study of Peri-operative Dostarlimab Monotherapy versus standard of care in Participants with Untreated Stage II/III dMMR/MSI-H | francesco.sclafani@hubruxelles.be | 3 | 3 | ||
| 28445 | unresectable liver metastases | Alain Hendlisz | Multiple | Highlight Therapeutics S.L. | BOT112-02 | Trial closed | Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer | alain.hendlisz@hubruxelles.be | 2 | 2 | |
| 28451 | Alain Hendlisz | Colon | Novartis | CADPT01C12101 | Trial closed | A Phase Ib multicenter, open-label dose escalation and expansion platform study of selected drug combinations in adult patients with advanced or metastatic BRAF V600 colorectal cancer | alain.hendlisz@hubruxelles.be | 1/1b | 1 | ||
| 22651 | Metastatic | Christiane Jungels | Multiple | Cantargia AB | CANFOUR | Trial closed | An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors | christiane.jungels@hubruxelles.be | 1/2 | 1 | |
| 22745 | metastatic, RECIST 1.1 | Alain Hendlisz | Colon | BMS - Bristol Myers Squibb int. | Checkmate 142 | Trial closed for recruitment | CA209-142 A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer. Checkmate 142 | alain.hendlisz@hubruxelles.be | 2 | 2 | |
| 22740 | MSI high/Mismatch Repair Deficient | Alain Hendlisz | Colon | BMS - Bristol Myers Squibb int. | CheckMate 8HW: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 8HW | Trial closed for recruitment | A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer. | alain.hendlisz@hubruxelles.be | 3 | 3 | |
| 29606 | Francesco Sclafani | Multiple | Novartis | CNIS793E12201 - daNIS-3 | Trial closed | daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) |
francesco.sclafani@hubruxelles.be | 2 | 2 | ||
| 29711 | Alain Hendlisz | Multiple | Bordet | COPERNIC | Trial open for recruitment | A study of on-treatment ctDNA changes in chemo-refractory colorectal cancer patients | alain.hendlisz@hubruxelles.be | ||||
| 22742 | colorectal cancer, metastatic or unresectable and for which standard treatments do not exist or are no longer effective. All standard chemotherapy agents (fluoropyrimidines, irinotecan and oxaliplatin) and monoclonal antibodies (bevacizumab, cetuximab an |
Alain Hendlisz | Colon | Institut Jules Bordet | CORIOLAN | Trial closed | CORIOLAN : Correlating the tumoral metabolic progression index measured by serial FDG PET-CT and apparent diffusion coefficient measured by MRI to patient's outcome in advanced colorectal cancer | alain.hendlisz@hubruxelles.be | |||
| 22692 | any line / Lung metastasis | Konstantinos Stathopoulos | Lung | EORTC | EORTC 1658 | Trial closed | Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) | konstantinos.stathopoulos@hubruxelles.be |